Table 2.

Schedule of study measures.

Assessment	Baseline In-person	Every week In-person or phone	Every month In-person	End-of-program In-person	12-week follow-up Phone
Primary outcome
PAI-1	X			X
Secondary outcomes
Blood pressure and heart rate	X		X	X
BMI and weight	X	X	X	X
Body composition	X		X	X
Cardiopulmonary fitness	X			X
Cholesterol	X			X
Dietary composition	X	X	X	X
Glycemic controla	X			X
HRQOL	X		X	X
Inflammationb	X			X
Liver enzymes	X			X
Liver histologyc	X			X (optional)
Markers of hemostasisd	X			X
MRI-PDFF/liver volume	X			X
Microbiome	X			X
NASH biomarkerse	X			X
NASH Clinical Decision Aidsf	X			X
PNPLA3 genotype	X
PNPLA3 expression	X			X
Covariates
Activity level	X	X	X	X	X
Medical/surgical/social history	X		X	X
NASH and other medications	X		X	X
Sociodemographics	X
Sleep quality	X	X	X	X

BMI = body mass index; HRQOL = health-related quality of life; MRI-PDFF = magnetic resonance imaging proton density fat fractionation; PNPLA3 = Patatin like phospholipase-3.

^aHemoglobin A1c, Insulin level, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

^bFerritin and White blood cell count.

^cNASH Activity Score and Fibrosis assessment.

^dAntithrombin, Factor VII, ADAMTS-13, D-dimer, Factor VIII, Fibrinogen, International Normalized Ratio (INR), P-selection, Platelet count, Protein S, Protein C, Thromboelastography (TEG), von Willebrand Factor.

^eAdiponectin, Cytokeratin (CK)-18.

^fNAFLD Fibrosis Score, Fibrosis-4 Index (FIB-4).